Advances in sickle cell therapies in the hydroxyurea era

Molecular Medicine

Volumn 20, Issue , 2014, Pages S37-S42

  Field, Joshua J ^a,b   Nathan, David G ^c,d,e  

^a Medical Sciences Institute   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEME; HEMOGLOBIN BETA CHAIN; HYDROXYUREA; MONOCLONAL ANTIBODY; NITRIC OXIDE; NKTT 120; REGADENOSON; RIVIPANSEL; SELG1; SILDENAFIL; UNCLASSIFIED DRUG;

ARTICLE; BETA GLOBIN GENE; CELL ADHESION; CELL THERAPY; DONOR; DRUG MEGADOSE; GENE; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HUMAN; INFLAMMATION; INVARIANT NATURAL KILLER T CELL; LOW DRUG DOSE; NATURAL KILLER T CELL; NONHUMAN; ONCOGENE; PULMONARY HYPERTENSION; REDUCED INTENSITY CONDITIONING; SICKLE CELL ANEMIA; TRANSFUSION; TUMOR SUPPRESSOR GENE; ANEMIA, SICKLE CELL; ANIMAL; DRUG EFFECTS;

ANEMIA, SICKLE CELL; ANIMALS; CELL ADHESION; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HUMANS; HYDROXYUREA; INFLAMMATION;

EID: 84922576733     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2014.00187     Document Type: Article

References (70)

1. Savitt TL, Goldberg MF. (1989) Herrick’s 1910 case report of sickle cell anemia: the rest of the story. JAMA. 261:266–71.
2. Herrick JB. (1910) Peculiar elongated and sickleshaped red blood corpuscles in a case of severe anemia. Arch. Intern. Med. 6:517–21.
3. Pauling L, et al. (1949) Sickle cell anemia: a molecular disease. Science. 110:543–8.
4. Platt OS, et al. (1991) Pain in sickle cell disease: rates and risk factors. N. Engl. J. Med. 325:11–6.
5. Castro O, et al. (1994) The acute chest syndrome in sickle cell disease: incidence and risk factors: the Cooperative Study of Sickle Cell Disease. Blood. 84:643–9.
6. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. (2005) Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine. 84:363–76.
7. Platt OS, et al. (1994) Mortality in sickle cell disease: life expectancy and risk factors for early death. N. Engl. J. Med. 330:1639–44.
8. Scott RB. (1970) Health care priority and sickle cell anemia. JAMA. 214:731–4.
9. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. (2010) Improved survival of children and adolescents with sickle cell disease. Blood. 115:3447–52.
10. Gaston MH, et al. (1986) Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N. Engl. J. Med. 314:1593–9.
11. Charache S, et al. (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N. Engl. J. Med. 332:1317–22.
12. Platt OS, et al. (1984) Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J. Clin. Invest. 74:652–6.
13. Steinberg MH, et al. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 289:1645–51.
14. Steinberg MH, et al. (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am. J. Hematol. 85:403–8.
15. Steinberg MH. (1997) Determinants of fetal hemoglobin response to hydroxyurea. Semin. Hematol. 34:8–14.
16. Lanzkron S, Carroll CP, Haywood C Jr. (2013) Mortality rates and age at death from sickle cell disease: U.S., 1979–2005. Public Health Rep. 128:110–6.
17. Xu J, et al. (2011) Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science. 334:993–6.
18. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. (2002) Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc. Natl. Acad. Sci. U. S. A. 99:3047–51.
19. Hebbel RP. (1997) Adhesive interactions of sickle erythrocytes with endothelium. J. Clin. Invest. 100:S83–6.
20. Hebbel RP, Osarogiagbon R, Kaul D. (2004) The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 11:129–51.
21. Kaul DK, Hebbel RP. (2000) Hypoxia/ reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J. Clin. Invest. 106:411–20.
22. Wallace KL, et al. (2009) NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFNgamma and CXCR3 chemokines. Blood. 114:667–76.
23. Tedder TF, Steeber DA, Chen A, Engel P. (1995) The selectins: vascular adhesion molecules. FASEB J. 9:866–73.
24. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7:678–89.
25. Chang J, et al. (2010) GMI-1070, a novel panselectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood. 116:1779–86.
26. Matsui NM, et al. (2001) P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood. 98:1955–62.
27. Matsui NM, Varki A, Embury SH. (2002) Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood. 100:3790–6.
28. Embury SH, et al. (2004) The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood. 104:3378–85.
29. Kutlar A, et al. (2012) A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am. J. Hematol. 87:536–9.
30. Telen MJ. (2014) Cellular adhesion and the endothelium: E-selectin, L-selectin, and pan-selectin inhibitors. Hematol. Oncol. Clin. North Am. 28:341–54.
31. Bernini JC, et al. (1998) Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood. 92:3082–9.
32. Griffin TC, McIntire D, Buchanan GR. (1994) High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N. Engl. J. Med. 330:733–7.
33. Quinn CT, et al. (2011) Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br. J. Haematol. 155:263–7.
34. Brennan PJ, Brigl M, Brenner MB. (2013) Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat. Rev. Immunol. 13:101–17.
35. Tupin E, Kinjo Y, Kronenberg M. (2007) The unique role of natural killer T cells in the response to microorganisms. Nat. Rev. Microbiol. 5:405–17.
36. Singh UP, Venkataraman C, Singh R, Lillard JW Jr. (2007) CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr. Metab. Immune Disord. Drug Targets. 7:111–23.
37. Wallace KL, Linden J. (2010) Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood. 116:5010–20.
38. Field JJ, et al. (2013) Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood. 121:3329–34.
39. Field JJ, Nathan DG, Linden J. (2011) Targeting iNKT cells for the treatment of sickle cell disease. Clin. Immunol. 140:177–83.
40. Field JJ, et al. (2013) A phase 1 single ascending dose study of NKTT120 in stable adult sickle cell patients [abstract]. Blood. 122:977.
41. Bertles JF, Milner PF. (1968) Irreversibly sickled erythrocytes: a consequence of the heterogeneous distribution of hemoglobin types in sickle-cell anemia. J. Clin. Invest. 47:1731–41.
42. Mohandas N, Hebbel R. (1994) Pathogenesis of Hemolytic Anemia. In: Sickle Cell Disease: Basic Principles and Clinical Practice. Embury SH, Hebbel RP, Mohandas N, Steinberg MH (eds.) New York, Raven Press, pp. 327–334.
43. Reiter CD, et al. (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat. Med. 8:1383–9.
44. Gladwin MT, et al. (2003) Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 107:271–8.
45. Belcher JD, et al. (2006) Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J. Clin. Invest. 116:808–16.
46. Belcher JD, et al. (2014) Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 123:377–90.
47. Ghosh S, et al. (2013) Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J. Clin. Invest. 123:4809–20.
48. Kato GJ, Gladwin MT, Steinberg MH. (2007) Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 21:37–47.
49. Bunn HF, et al. (2010) Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 116:687–92.
50. Gladwin MT, et al. (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N. Engl. J. Med. 350:886–95.
51. Parent F, et al. (2011) A hemodynamic study of pulmonary hypertension in sickle cell disease. N. Engl. J. Med. 365:44–53.
52. Machado RF, et al. (2011) Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood. 118:855–64.
53. Schmidtko A, Tegeder I, Geisslinger G. (2009) No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing. Trends Neurosci. 32:339–46.
54. Adedeji MO, Cespedes J, Allen K, Subramony C, Hughson MD. (2001) Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch. Pathol. Lab. Med. 125:1436–41.
55. Weil JV, et al. (1993) NHLBI Workshop Summary: Pathogenesis of lung disease in sickle hemoglobinopathies. Am. Rev. Respir. Dis. 148:249–56.
56. Klings ES, et al. (2014) An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am. J. Respir. Crit. Care Med. 189:727–40.
57. Johnson FL, et al. (1984) Bone-marrow transplantation in a patient with sickle-cell anemia. N. Engl. J. Med. 311:780–3.
58. Walters MC, et al. (1996) Bone marrow transplantation for sickle cell disease. N. Engl. J. Med. 335:369–76.
59. Bhatia M, Walters MC. (2008) Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. Bone Marrow Transplant. 41:109–17.
60. Hsieh MM, et al. (2009) Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N. Engl. J. Med. 361:2309–17.
61. Srinivasan R, et al. (2006) Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br. J. Haematol. 133:305–14.
62. Hsieh MM, et al. (2014) Nonmyeloablative HLAmatched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 312:48–56.
63. Bolanos-Meade J, et al. (2012) HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 120:4285–91.
64. Levasseur DN, et al. (2004) A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin. J. Biol. Chem. 279:27518–24.
65. Pawliuk R, et al. (2001) Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 294:2368–71.
66. Pestina TI, et al. (2009) Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol. Ther. 17:245–52.
67. Perumbeti A, et al. (2009) A novel human gammaglobin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood. 114:1174–85.
68. Chandrakasan S, Malik P. (2014) Gene therapy for hemoglobinopathies: the state of the field and the future. Hematol. Oncol. Clin. North Am. 28:199–216.
69. Hanna J, et al. (2007) Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 318:1920–3.
70. Townes TM. (2008) Gene replacement therapy for sickle cell disease and other blood disorders. Hematology Am. Soc. Hematol. Educ. Program. 2008:193–6.